Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal
Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom+2Reuters+2 The transaction gives Abbott an immediate leadership position in fast‑growing cancer screening and precision oncology diagnostics, anchored by Exact Sciences’ flagship tests Cologuard and Oncotype DX, plus its new multi‑cancer blood test Cancerguard. Abbott MediaRoom+2investor.exactsciences.com+2 Deal Terms: $105 per Share and a $23 Billion Enterprise Value Under the definitive agreement announced today, Abbott will